Last modified on Thu 17 Dec 2020 17.58 EST
An advisory committee for the US Food and Drug Administration (FDA) has recommended the agency authorize a second Covid-19 vaccine, this one developed by Moderna and the National Institute of Allergy and Infectious Diseases (NIAID).
The recommendation paves the way for the FDA to give emergency approval for a second highly effective vaccine to be used in the US. That approval could come by the end of the week. An FDA analysis found Moderna’s vaccine is more than 94% effective at preventing Covid-19 in a trial of more than 30,000 participants.
The likely authorization of the second vaccine comes after more than 300,000 Americans have succumbed to Covid-19, in a winter-time “third wave” of the disease that is filling hospitals with patients and exhausting healthcare workers.
by: MATTHEW PERRONE and LAURAN NEERGAARD, Associated Press
Posted:
Dec 17, 2020 / 09:57 PM EST
WASHINGTON (AP) The head of the Food and Drug Administration said late Thursday that his agency will move to quickly authorize the second COVID-19 vaccine to fight the pandemic, hours after the shot won the key endorsement of a government advisory panel.
FDA Commissioner Stephen Hahn said in a statement that regulators have communicated their plans to drugmaker Moderna, which co-developed the vaccine with the National Institutes of Health. The announcement came after a panel of FDA advisers, in a 20-0 vote, ruled that the benefits of the vaccine outweighed the risks for those 18 years old and up.
FDA advisory panel endorses Moderna s coronavirus vaccine themonitor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themonitor.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Seattle Cancer Care Alliance Among First Washington Healthcare Providers to Receive COVID-19 Vaccine
December 15, 2020 GMT
Seattle Cancer Care Alliance (SCCA), the only
National Comprehensive Cancer Network (
NCCN )- member cancer center in Washington state, was selected by the Washington State Department of Health to be one of the first 17 sites to receive the recently authorized COVID-19 vaccine. SCCA will receive a portion of the 32,000 doses allotted to Washington State hospitals and will vaccinate its staff, helping to protect the vulnerable patient population that SCCA serves and preserving access to cancer care in the Puget Sound region.